PR84771

SAN DIEGO and SAFFRON WALDEN, United Kingdom, July 14, 2020 /PRNewswire=KYODO JBN/ --

Invivoscribe, Inc., an industry pioneer and global leader in the field of

precision diagnostics announces the launch of a fully integrated drug

development engine. This new engine will combine with its in-house expertise in

diagnostics development and worldwide access to patients and clinical testing

capabilities to accelerate drug development.

Logo - https://mma.prnewswire.com/media/1019746/Invivoscribe_Logo.jpg

Invivoscribe's therapeutics division also announced today that the company has

in-licensed technology involving a preclinical molecule and associated small

molecules from Domainex Ltd. Domainex is a rapidly growing, well established

integrated drug discovery service company in the UK that has utilized its

novel, proprietary technologies to develop a first-in-class small molecule

program against a difficult to target enzyme. Under the license agreement,

Invivoscribe will develop and commercialize certain molecules generated by

Domainex as oral immunotherapy agents to treat hematological malignancies,

including acute myeloid leukemia. The overall financial aspects of the deal

include an upfront payment and subsequent milestone payments based on various

phases of drug development, regulatory submission and commercialization,

including royalties on the resulting commercial products.

"The launch of Invivoscribe Therapeutics was an obvious next step for

Invivoscribe. We have assembled an extraordinary team of drug development

experts with decades of experience leading discovery, preclinical development,

and directing pharmaceutical sciences. They are well versed in taking small

molecules through all phases of candidate selection into human trials. They've

joined our diagnostics, bioinformatics, and regulatory teams that have years of

experience using our tests to assist pharma companies in getting their drugs

approved worldwide, and our international network of LabPMM clinical

laboratories with ready access to oncology patients. All of our interactions

with Domainex have been extremely positive and we are impressed with the

molecules they have discovered," said Jeffrey Miller, CSO & CEO of Invivoscribe.

Dr. Tom Mander, CEO of Domainex, added, "This license agreement reflects the

extensive capabilities of Domainex to generate molecules with therapeutic

potential. We are delighted that Invivoscribe has decided to invest in moving

the program through drug development ultimately to approval and

commercialization. This deal is in keeping with our strategy to grow rapidly

our drug discovery service business to enrich the pipelines of our partners. I

want to thank all of our scientists who have worked on the program and

acknowledge the support we have received along the way. I wish Jeff and his

team every success with the program and the launch of their new division."

About Invivoscribe

Invivoscribe has been Improving Lives with Precision Diagnostics® for more than

twenty-five years, advancing the field of precision medicine by developing and

selling standardized reagents, tests, and bioinformatics tools to more than 700

customers in 160 countries. Invivoscribe also has a significant impact on

global health working with pharmaceutical companies to accelerate approvals of

new drugs and treatments by supporting international clinical trials,

developing, commercializing companion diagnostics, and providing expertise in

both regulatory and laboratory services. With its proven ability to provide

global access to distributable reagents, kits, and controls, as well as

clinical trial services through our international clinical lab subsidiaries

(LabPMM), Invivoscribe has demonstrated it is an ideal partner. For additional

information please contact Invivoscribe at: customerservice@invivoscribe.com or

visit: www.invivoscribe.com.

About Domainex:

Domainex is a leading, award-winning integrated medicines research service

partner working with ambitious life science organisations from around the

globe. We have been setting new standards in research since 2001, working

collaboratively with pharmaceutical and biotechnology companies, patient

foundations and leading academic institutions.

We provide innovative and customised biology and chemistry services to advance

the disease research projects of our partners, from target expression to

pre-clinical development candidate nomination. Working with Domainex maximises

the chance of successful progression for our partners' research and our

approach consistently saves up to 30% of the time needed to discover new

medicines by comparison with the industry average. Our innovative science and

extensive technical capabilities enable us to produce novel medicines to treat

diseases with strong commercial potential. We work closely and collaboratively

with our clients to understand their aspirations, bringing our ideas, know-how

and wealth of experience to bear on their projects.

Our highly qualified and experienced team of dedicated research scientists has

an unrivalled breadth of knowledge, access to a wide range of technologies and

a proven track record of successful innovation in solving research challenges

including being named on over 60 patent applications and the invention of

numerous candidate drugs. We aim to deliver successful outcomes efficiently and

quickly, setting the highest possible benchmark in medicines research.

Full information about Domainex and our award-winning services can be found at

www.domainex.co.uk.

SOURCE: Invivoscribe, Inc.

CONTACT: Domainex, Dr Tom Mander, E: tom.mander@domainex.co.uk, or Media

Relations, Sciad Communications, Deborah Cockerill / Juliette Craggs / Victoria

Deaner, T: +44(0)20 3405 7892, E: domainex@sciad.com